SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
SEC Accession No. 0001819790-23-000022
Filing Date
2023-04-28
Accepted
2023-04-28 20:01:25
Documents
3
Period of Report
2023-04-24

Document Format Files

Seq Description Document Type Size
1 FORM 3/A wf-form3a_168272646901977.html 3/A  
1 FORM 3/A wf-form3a_168272646901977.xml 3/A 2888
2 JEFFREY FARROW POA farrowpoa-exhibit24.htm EX-24 4183
3 GRAPHIC farrowpoa-exhibit24001.jpg GRAPHIC 236007
  Complete submission text file 0001819790-23-000022.txt   333595
Mailing Address TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080
Business Address
Farrow Jeffrey S (Reporting) CIK: 0001405253 (see all company filings)

Type: 3/A | Act: 34 | File No.: 001-39614 | Film No.: 23869443

Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Issuer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)